Dallas-based Spark Biomedical, an innovator in drug-free wearable neurostimulation technology, has named Anja Krammer as its new chief executive officer.
Krammer has extensive expertise scaling healthcare and medical technology companies, turning breakthrough innovations into commercially successful products across clinical and consumer markets, Spark said. She has served on public and private company boards and held senior executive roles advancing clinical and commercialization solutions in cardiac, dermatology, and women’s health therapies.
Spark Biomedical Board Chair Matt Harrison said his company is “changing many lives for the better through its novel platform.”
“Anja’s leadership, experience, and scientific rigor will take the company to new and exciting heights allowing it to serve so many more that will benefit from Spark’s therapies,” he added in a statement. “The board is excited to partner with Anja as she leads Spark through its next phase of clinical validation, regulatory advancement, and global commercialization.”
Accelerating company growth

Spark Biomedical’s Sparrow Ascent device [Image: Spark]
Spark Biomedical has developed proprietary neuromodulation technology targeting the vagus and trigeminal cranial nerves, with applications including mental health, women’s health, hemostasis, bleeding disorders, and broader wellness indications. Spark’s patented tech has been utilized by a number of institutions engaged in the application of neurostimulation for health improvement. The company said it is advancing both regulated clinical products and consumer solutions built on the same scientific foundation.
“I’m honored to join Spark Biomedical as CEO,” Krammer said in a statement. “Our innovative technology platform and exceptional team position us to accelerate growth, deliver strong stakeholder value, and lead the bioelectronic medicine market to improve patient health. I look forward to building on our foundation to achieve superior clinical outcomes and commercial success.”
Krammer will focus on accelerating company growth by advancing Spark’s clinical programs and regulatory pathways, adding commercial capabilities across healthcare and consumer channels, bolstering strategic partnerships, and fueling a sustainable rise in revenue.
Krammer, who assumed her role as CEO on May 4th, will also serve on Spark’s board. Outgoing CEO and cofounder Daniel Powell will now focus on one of Spark’s latest products, the “Neural Tourniquet,” which stimulates the body’s clotting response, leading it through FDA approval and commercialization.
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.












